Incidence of Malignant Arrhythmias Requiring Hospitalization After Starting Donepezil
Overview
This study investigates the association between donepezil use and hospitalization for malignant arrhythmias in older adults.
Background
Alzheimer's disease (AD) is a growing concern with an expected increase in prevalence among the aging population. Acetylcholinesterase inhibitors (AChEIs), particularly donepezil, are commonly prescribed for AD, but they carry risks of serious cardiac side effects, including malignant arrhythmias, as indicated in the pharmacological literature.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
Donepezil is associated with a higher risk of acquired long-QT syndrome (aLQTS) compared to other AChEIs.
Malignant arrhythmias, including torsades de pointes (TdP), may occur more frequently in patients taking donepezil.
Donepezil inhibits the cardiac delayed rectifier potassium current (IKr), contributing to its arrhythmogenic potential.
Advanced age and female sex are common risk factors for both malignant arrhythmias and Alzheimer's disease.
CredibleMeds lists donepezil as a known-risk medication for QT prolongation.
Clinical Implications
Clinicians should be vigilant when prescribing donepezil, particularly in older patients who may have additional risk factors for cardiac arrhythmias. Monitoring for signs of QT prolongation and considering ECG assessments may be warranted in at-risk populations.
Conclusion
The findings suggest a need for careful consideration of the cardiac risks associated with donepezil in older adults with Alzheimer's disease. Further research is necessary to clarify the extent of these risks in clinical practice.
Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.
